#今日行业热点#

①Nature：The next generation of coronavirus vaccines: a graphical guide

下一代冠状病毒疫苗图解指南
②Gut：Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer

YTHDF1可增强结直肠癌的抗肿瘤免疫并增强抗PD-1的疗效

DOI :10.1136/gutjnl-2022-328845

③Journal of Medical Virology：Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity

横断面分析揭示了与COVID-19严重程度相关的自身抗体特征，自身抗体或为自身免疫性疾病的潜在治疗靶点

DOI :10.1002/jmv.28538

④Gut：Inflammation-associated gut microbiome in postacute sequelae of SARS-CoV-2 points towards new therapeutic targets

长期COVID-19中与炎症相关肠道微生物群指向了新的治疗靶点

DOI :10.1136/gutjnl-2022-328757

⑤Translational Neurodegeneration：Links between COVID-19 and Parkinsons disease/Alzheimers disease: reciprocal impacts, medical care strategies and underlying mechanisms

COVID-19与帕金森病/阿尔茨海默病之间的联系:相互影响、医疗策略和潜在机制

DOI :10.1186/s40035-023-00337-1

⑥EMBO Molecular Medicine：Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking

靶向Brg1-CXCL14轴通过驱动中性粒细胞转运参与酒精性肝损伤

DOI :10.15252/emmm.202216592

⑦达雷妥尤单抗生物类似药HLX15(重组抗CD38全人单克隆抗体注射液）在中国男性健康受试者中开展的1期临床研究完成首例受试者给药

⑧注射用ADC药物SHR-A1811临床试验获批，开展用于HER2低表达乳腺癌治疗的临床试验

⑨重组人促甲状腺激素（rhTSH）用于分化型甲状腺癌术后辅助放射性碘清甲治疗以及术后辅助诊断的两个适应症III期临床研究进展顺利

⑩全球首个经FDA、EMA批准，拥有CLDT、ITP双适应症的血小板生成素受体激动剂（TPO- RA）马来酸阿伐曲泊帕片申报获CDE受理

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！